340B Program Faces Potential Overhaul Following Court Rulings

Published: 2026/02/15 00:52:38

The future of the 340B Drug Pricing Program is onc again under review⁢ as the Department of Health and Human services (HHS) considers redesigning its ‍stalled rebate model pilot program. This comes after⁢ two federal court rulings blocked the initial implementation and HHS later agreed to abandon the original initiative [[2]].

What is the 340B Program?

The 340B program is a government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations – such as hospitals and clinics – ‍at significantly reduced prices. These entities, often serving vulnerable communities, then use these ⁣savings to stretch federal resources and expand patient access to care [[1]].

The Abandoned Rebate model and Legal Challenges

In August, HHS announced a pilot program that would have shifted 340B hospitals from receiving upfront discounts to a rebate model. This would have required hospitals to pay full market prices ⁣for drugs and then seek reimbursement through a rebate system. The American Hospital Association (AHA) and othre plaintiffs immediately challenged the change in court, arguing it would impose significant financial burdens and jeopardize care for patients in rural and ⁤underserved areas.

The ⁣U.S.District Court for the District of Maine issued a preliminary injunction against the program on December 29th. The 1st U.S. circuit Court of Appeals⁤ later denied the government’s request to stay the injunction on January 7th. Recognizing the legal challenges, HHS filed a ⁣motion on February 5th asking the court to remand ‍the issue back⁤ to the Health Resources and Services Administration (HRSA). The district court subsequently vacated and remanded ⁢the program on February 10th⁤ [source].

HRSA Seeks ⁤Input on⁢ a New Model

On February 13th, HRSA issued a Request for Information (RFI) to⁢ gather feedback ⁣from stakeholders on a potential rebate-based model for ⁤the 340B program. The comment period is open until March 19th. This signals that HHS is exploring choice approaches to address concerns about drug⁢ pricing and program integrity.

aimee Kuhlman,⁣ vice president of advocacy and grassroots at the American Hospital Association, stated that the AHA “welcomes HRSA’s attempt to gather detailed information about the impact of a⁣ rebate‍ model.” She emphasized the need for HHS to reconsider policies that could shift costs onto hospitals serving vulnerable populations [[[[[source]].

What to Expect next

Any new rebate program proposed by HHS will be subject to public notice, a comment period, and a delayed effective date of⁢ at least 90 days after manufacturer approvals are announced. The agency’s decision to seek⁤ input suggests a willingness to⁢ consider alternative solutions that balance the goals of affordability, access, and program sustainability.

Key Takeaways:

• The original 340B rebate model pilot program has been blocked by⁤ federal courts.
• HHS is now seeking⁤ input on a potential ⁣redesigned rebate model.
• The American ⁣Hospital Association and other stakeholders are advocating for policies that protect access to care for vulnerable communities.
• Any new program will require a public comment period and a ⁤delayed ⁣implementation.

The 340B ⁢program remains a critical component of the healthcare safety net. The ongoing debate over its structure highlights the complex challenges of balancing drug⁤ affordability, manufacturer ⁤incentives, and the needs of patients and providers.